ArticleAnnals of surgical oncology2025
Detection of Exhaled Volatile Organic Compounds as Noninvasive Biomarkers for Pancreatic Adenocarcinoma.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExhaled volatile organic compounds (VOC) have shown promise as noninvasive biomarkers in lung cancer and pulmonary diseases. This study aimed to evaluate the role of VOC as a noninvasive biomarker for pancreatic adenocarcinoma (PDAC) and explore whether elevated VOC levels correlate with clinical characteristics such as tumor size and cancer antigen (CA)19-9 levels. PATIENTS AND
methodsA total of 25 patients with PDAC and 23 matched control subjects were enrolled. Exhaled breath was collected and analyzed using a silicon microreactor and ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). Univariate analyses, Spearman correlations, and penalized regression (SCAD), along with area under the receiver-operating characteristic (ROC) curves (AUC) identified the top VOC biomarkers. VOC concentrations exceeding the 75th percentile of controls were deemed elevated with subgroup analysis comparing patients with all three elevated VOC to those without.
resultsFive VOC (heptanone, hexanal, hexanone, malondialdehyde (MDA), and acetaldehyde) were consistently and significantly higher in patients with PDAC. The penalized regression and linear discriminant analysis (LDA) identified three top VOC (acetaldehyde, MDA, hexanone) that distinguished PDAC from controls with an AUC of 0.81. Patients exhibiting elevated levels of all three compounds had smaller tumors and lower CA19-9 levels (p < 0.05).
conclusionsA distinctive profile of elevated exhaled VOC, particularly hexanone, acetaldehyde, and MDA, is associated with PDAC. These findings suggest that VOC analysis could be a novel, noninvasive method for early detection of pancreatic cancer. Further studies in larger cohorts are warranted to validate these results.
Indexed as
Identifiers
40550959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.